Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors -





Published: February 2014 | Pages: 70 | Format: PDF and Online

The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Recently, VEGF-Trap Eye originating from Regeneron Pharmaceuticals has been approved for cancer and ophthalmic indications. Combined sales of all four VEGF targeting products were US$ 13,192 mln in 2013, of which 53.4% were from oncology sales.

The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation „biobetter or biosuperior“ molecules as well as of biosimilar copies of the originator products.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents 

1. Bevacizumab Biosimilars and Biosuperiors
Marketed VEGF Antibodies
-           Avastin Sales & Pipeline
-           Zaltrap Sales & Pipeline
“Next Generation Avastin” Pipeline
-           Anti-VEGF Antibody Pipeline
-           Anti-VEGF-Receptor Antibody Pipeline
-           Bispecific Anti-VEGF Antibody Pipeline
Avastin Biosimilar Pipeline

2. Ranibizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody
-           Lucentis Sales & Pipeline
-           Eylea Sales & Pipeline
“Next Generation Lucentis” Pipeline
Lucentis Biosimilar Pipeline

3.  Corporate VEGF Antibody Biosimilar & Biobetter Pipelines